448 research outputs found
Hematopoietic Cell Transplantation for Juvenile Myelomonocytic Leukemia
No full textJuvenile myelomonocytic leukemia (JMML) is a rare myeloproliferative disorder of early childhood; it is characterized by hepatosplenomegaly and organ infiltration due to excessive proliferation of cells of the monocytic and granulocytic lineages. Approximately 85% of JMML patients harbor in their leukemia cells either somatic or germline mutations in the genes PTPN-11, NRAS, KRAS, NF1, or CBL. Allogeneic hematopoietic stem cell transplantation (HSCT) remains the therapy of choice for the majority of affected children. Available data indicate that transplantation from an HLA-identical sibling or a matched unrelated volunteer can cure more than 50% of patients. A similar proportion of children with JMML, especially when transplanted from donors with limited HLA disparity, can be cured with umbilical cord blood transplantation, which can represent a suitable option for children with JMML lacking either a related or an unrelated HSCT donor
Allogeneic Hematopoietic Cell Transplantation for Acute Myeloid Leukemia.
No full textAllogeneic stem cell transplantation is an increasingly important treatment option in the management of adult acute myeloid leukemia (AML). The major causes of treatment failure remain disease relapse and treatment toxicity. In this review, Dr Vyas presents an overview of important recent data defining molecular factors associated with treatment failure in AML. He also identifies the emerging importance of leukemia stem cell biology in determining both response to therapy and relapse risk in AML. Dr Appelbaum discusses advances in the design and delivery of both myeloablative and reduced-intensity conditioning regimens, highlighting novel strategies with the potential to improve outcome. Dr Craddock discusses the development of both novel conditioning regimens and post-transplantation strategies aimed at reducing the risk of disease relapse
The Foregoing Letter was sent for Comment to Drs. Appelbaum and Deisseroth who Reply as Follows:
No full textFamily Assessment- Author Index
No full textAuthor Index (12 pages)
A-Z
A
Abbott, D.: 263 Abery, B.: 242 Abidin, R: 81, 265 Abramovitch, R: 134, 135, 136, 137, 139,142,143,144,145,146 Abril, s.: 118 Achenbach, T. M.: 12,47, 118, 223, 265 Acock, A. c.: 206 Adams, G. R: 205 Adams, S. J.: 226 Al-Khayyal, M.: 74 Alexander, J. F.: 75 Allisson, P. D.: 185 Alwin, D. F.: 182,191,194 Amato, P. R: 205- 231, 206, 207, 210, 213,215,216, 219, 221, 222, 224, 227,230 Ammerman, R : 263 Amoloza, T. 0 .: 170, 171,172,176, 179, 187, 188 Anastasi, A.: 265 Anderson, B. J.: 85 Anderson, c.: 117 Anderson, P. P.: 104 Anderson, S. A.: 79, 168, 177 Anthony, J.: 117 Apley, J.: 84 Aponte, H. J.: 117 Appelbaum, M.: 263 Arrington, A.: 11 Asher, S.: 82 Asterita, M. F. : 92 Attneave, c.: 121 Auslander, W. F: 85
Z
Zane, N .: 107, 119 Zetlin, A.: 263 Zill, N.: 83 Zuo, J.: 171, 180, 18
Family Assessment- Author Index
No full textAuthor Index (12 pages)
A-Z
A
Abbott, D.: 263 Abery, B.: 242 Abidin, R: 81, 265 Abramovitch, R: 134, 135, 136, 137, 139,142,143,144,145,146 Abril, s.: 118 Achenbach, T. M.: 12,47, 118, 223, 265 Acock, A. c.: 206 Adams, G. R: 205 Adams, S. J.: 226 Al-Khayyal, M.: 74 Alexander, J. F.: 75 Allisson, P. D.: 185 Alwin, D. F.: 182,191,194 Amato, P. R: 205- 231, 206, 207, 210, 213,215,216, 219, 221, 222, 224, 227,230 Ammerman, R : 263 Amoloza, T. 0 .: 170, 171,172,176, 179, 187, 188 Anastasi, A.: 265 Anderson, B. J.: 85 Anderson, c.: 117 Anderson, P. P.: 104 Anderson, S. A.: 79, 168, 177 Anthony, J.: 117 Apley, J.: 84 Aponte, H. J.: 117 Appelbaum, M.: 263 Arrington, A.: 11 Asher, S.: 82 Asterita, M. F. : 92 Attneave, c.: 121 Auslander, W. F: 85
Z
Zane, N .: 107, 119 Zetlin, A.: 263 Zill, N.: 83 Zuo, J.: 171, 180, 18
Reprint of: Allogeneic Hematopoietic Cell Transplantation for Acute Myeloid Leukemia
No full textAbstractAllogeneic stem cell transplantation is an increasingly important treatment option in the management of adult acute myeloid leukemia (AML). The major causes of treatment failure remain disease relapse and treatment toxicity. In this review, Dr Vyas presents an overview of important recent data defining molecular factors associated with treatment failure in AML. He also identifies the emerging importance of leukemia stem cell biology in determining both response to therapy and relapse risk in AML. Dr Appelbaum discusses advances in the design and delivery of both myeloablative and reduced-intensity conditioning regimens, highlighting novel strategies with the potential to improve outcome. Dr Craddock discusses the development of both novel conditioning regimens and post-transplantation strategies aimed at reducing the risk of disease relapse
Is There Market Power in the French Comte Cheese Market?
No full textAn NEIO approach is used to measure seller market power in the French Comté cheese market, characterised by government-approved supply control. The estimation is performed on quarterly data at the wholesale stage over the period 1985-2005. Three different elasticity shifters are included in the demand specification, and the supply equation accounts for the existence of the European dairy quota policy. The market power estimate is small and statistically insignificant. Monopoly is rejected, as well as weak forms of Cournot oligopoly. Results appear to be robust to the choice of functional form, and suggest little effect of the supply control scheme on consumer prices.Supply control, NEIO, protected designation of origin, Marketing,
Unrelated hematopoietic stem cell donors as research subjects
No full texthttp://dx.doi.org/10.1038/bmt.2010.26
- …
